A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: The tirofiban evaluation of novel dosing versus abciximab wi-Reference-Cited by-同舟云学术

A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: The tirofiban evaluation of novel dosing versus abciximab wi

Published:2011-01-11 Issue:7 Volume:77 Page:1001-1009
ISSN:1522-1946
Container-title:Catheterization and Cardiovascular Interventions
language:en
Short-container-title:Cathet. Cardiovasc. Intervent.

Author:

Moliterno David J.,

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,Radiology Nuclear Medicine and imaging,General Medicine

Reference11 articles.

1. TARGET Investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization;Topol;N Engl J Med,2001

2. Increased concentrations of Tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of Tirofiban;Schneider;Am J Cardiol,2003

3. Enhanced early inhibition of platelet aggregation with an increased bolus of Tirofiban;Schneider;Am J Cardiol,2002

4. Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention;Herrmann;Am J Cardiol,2002

5. A clinical trial of abciximab in elective percutaneous coronary intervention after clopidogrel pretreatment;Kastrati;N Engl J Med,2004

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Ischemic and Bleeding Events Between Short-Duration Versus Long-Duration Tirofiban Regimens in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention;Journal of Cardiovascular Pharmacology;2022-07

2. Practicability of Bivalirudin plus Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis;Clinical and Applied Thrombosis/Hemostasis;2021-01

3. Non-inferiority trials using a surrogate marker as the primary endpoint: An increasing phenotype in cardiovascular trials;Clinical Trials;2020-08-24

4. Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology;Thrombosis and Haemostasis;2019-12-09

5. Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic;Pharmacology & Therapeutics;2019-11